domesticsale.info - Topical Otic Therapy Recommendations for Bacterial Acute Otitis

BUY NOW For Sale 70%!
buy viagra

Fraxiparine renal dose ciprofloxacin

  • 1.

    fraxiparine renal dose ciprofloxacin

    Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328–340PubMedGoogle Scholar

  • 2.

    Hersh EM, Bodey GP, Nies BA, Freireich EJ (1965) Causes of death in acute leukemia. A ten-year study of 414 patients from 1954-1963. JAMA 193:105–109PubMedGoogle Scholar

  • 3.

    Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH (1972) Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann Intern Med 77(5):707–714PubMedGoogle Scholar

  • 4.

    De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP (1994) Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 120(10):834–844PubMedGoogle Scholar

  • 5.

    Viscoli C, EORTC International Antimicrobial Therapy Group (2002) Management of infections in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATCG). Eur J Cancer 38(Suppl 4):S82–S87PubMedGoogle Scholar

  • 6.

    Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19(8):2201–2205PubMedGoogle Scholar

  • 7.

    Blijlevens NMA (2005) Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol 17(6):605–610PubMedGoogle Scholar

  • 8.

    Fainstein V, Rodriguez V, Turck M, Hermann G, Rosenbaum B, Bodey GP (1981) Patterns of oropharyngeal and fecal flora in patients with acute leukemia. J Infect Dis 144(1):10–18PubMedGoogle Scholar

  • 9.

    The EORTC International Antimicrobial Therapy Cooperative Group (1987) Ceftazidime combined with a short or long course of amikacin for empiric therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317(27):1692–1698Google Scholar

  • 10.

    Klastersky J, Zinner SH, Calandra T et al (1988) Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 24(Suppl 1):S35–S45PubMedGoogle Scholar

  • 11.

    (1991) The EORTC International Antimicrobial Therapy Cooperative Group and National Cancer Institute of Canada. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163(5):951-958Google Scholar

  • 12.

    (1993) The International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and neutropenia. Ann Intern Med 119:584–593Google Scholar

  • 13.

    Cometta A, Zinner S, De Bock R et al (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 39(2):445–452PubMedGoogle Scholar

  • 14.

    Cometta A, Calandra T, Gaya H et al (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40(5):1108–1115PubMedGoogle Scholar

  • 15.

    Marchetti O, Calandra T (2002) Infections in neutropenic cancer patients. Lancet 359(9308):723–725PubMedGoogle Scholar

  • 16.

    Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO (1984) Hickman catheter infections in patients with malignancies. Medicine (Baltimore) 63:189–200Google Scholar

  • 17.

    Raad II, Bodey GP (1992) Infectious complications of indwelling vascular catheters. Clin Infect Dis 15:197–210PubMedGoogle Scholar

  • 18.

    Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110PubMedGoogle Scholar

  • 19.

    Nucci M, Spector N, Bueno AP et al (1997) Risk factors and attributable mortality associated with superinfection in neutropenic patients with cancer. Clin Infect Dis 25:572–579Google Scholar

  • 20.

    Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA (1984) Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100:345–351PubMedGoogle Scholar

  • 21.

    Chang HY, Rodrigues V, Narboni G et al (1976) Causes of death in adults with acute leukemia. Medicine 55:259–268PubMedGoogle Scholar

  • 22.

    Hughes WT, Armstrong DA, Bodey GP et al (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedGoogle Scholar

  • 23.

    Donelly JP (1991) For debate: assessment and reporting of clinical trials of empirical therapy in neutropenic patients. J Antimicrob Chemother 27:377–378Google Scholar

  • 24.

    Feld R (1998) Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement? Support Care Cancer 6:444–448PubMedGoogle Scholar

  • 25.

    Sickles EA, Greene WH, Wiernik PH (1975) Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135:715–719PubMedGoogle Scholar

  • 26.

    Slavin MA, Grigg AP, Schwartzer AP et al (2007) A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. Bone Marrow Transplant 40:157–163PubMedGoogle Scholar

  • 27.

    Elting LS, Rubenstein EB, Rolston KVI, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247–259PubMedGoogle Scholar

  • 28.

    Anderson KC, Lew MA, Gorgone BC, Martel J, Leamy CB, Sullivan B (1986) Transfusion-related sepsis after prolonged platelet storage. Am J Med 81:405–411PubMedGoogle Scholar

  • 29.

    Verhagen C, Stalpers LJA, De Pauw BE, Haanen C (1987) Drug induced skin reactions in patients with acute non-lymphocytic leukaemia. Eur J Haematol 38:225–230PubMedGoogle Scholar

  • 30.

    Klastersky J (1994) Non-infectious causes of fever in cancer patients. In: Glauser MP, Calandra T (eds) Baillière’s clinical infectious diseases. Baillière Tindall, London, pp 439–53Google Scholar

  • 31.

    Wade JC, Schimpff SC, Newman KA, Wiernik PH (1982) Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 97:503–508PubMedGoogle Scholar

  • 32.

    Lina B, Forey F, Troncy J, Greenland T, Fleurette J, Etienne J (1994) Oral source of staphylococcus epidermidis septicaemia in a neutropenic patient. Eur J Clin Microbiol Infect Dis 13(9):773–775PubMedGoogle Scholar

  • 33.

    Costa SF, Barone AA, Miceli MH et al (2006) Colonization and molecular epidemiology of coagulase-negative Staphylococcal bacteremia in cancer patients: a pilot study. Am J Infect Control 34:36–40PubMedGoogle Scholar

  • 34.

    Wade JC, Schimpff SC, Newman KA, Fortner CL, Standiford HC, Wiernik PH (1981) Piperacillin or ticarcillin plus amikacin: a double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 71:983–990PubMedGoogle Scholar

  • 35.

    Duprez P, Michaux JL (1981) Piperacillin or cefotaxime plus amikacin: result of empirical antibiotic therapy for febrile episodes in granulocytopenic patients. Proceedings of the 12th International Congress of chemotherapy. Florence, Italy; July 19–24Google Scholar

  • 36.

    Winston DJ, Ho WG, Young LS et al (1982) Piperacillin plus amikacin therapy v carbenicillin plus amikacin therapy in febrile granulocytopenic patients. Arch Intern Med 142:1663–1667PubMedGoogle Scholar

  • 37.

    Winston DJ, Barnes RC, Ho WG, Young LS, Champlin RE, Gale RP (1984) Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med 77:442–450PubMedGoogle Scholar

  • 38.

    Winston DJ, Ho WG, Bruckner D, Gale RP, Champlin RE (1988) Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med 85(1a):21–30PubMedGoogle Scholar

  • 39.

    Sage R, Han I, Prentice HG et al (1988) A randomized trial of empirical antibiotic therapy with one of four beta-lactam antibiotics in combination with netilmicin in febrile neutropenic patients. J Antimicrob Chemother 22:237–247PubMedGoogle Scholar

  • 40.

    Feliu J, Artal A, Gonzlaez Baron M et al (1992) Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer. Antimicrob Agents Chemother 36:2816–2820PubMedGoogle Scholar

  • 41.

    De Pauw BE, Boogaerts MA, Demuynck H et al (1995) Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 36:185–200Google Scholar

  • 42.

    Feld R, de Pauw BE, Berman S, Keating A, Ho W (2000) Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 18:3690–3698PubMedGoogle Scholar

  • 43.

    Del Favero A, Menichetti F, Martino P et al (2001) A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33:1295–1301PubMedGoogle Scholar

  • 44.

    Bow EJ, Rotstein C, Noskin GA et al (2006) Randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43:447–459PubMedGoogle Scholar

  • 45.

    Paul M, Soares-Weiser L, Leibovici L (2003) β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 326(7399):1111PubMedGoogle Scholar

  • 46.

    Galloe AM, Graudal N, Christensen HR et al (1995) Aminoglycosides: single or multiple daily dosing? A meta-analysis in efficacy and safety. Eur J Clin Pharmacol 48:39–43PubMedGoogle Scholar

  • 47.

    Munckhof WJ, Grayson ML, Turnodge JD (1996) A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 37:645–663PubMedGoogle Scholar

  • 48.

    Ali MZ, Goetz MB (1997) A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:796–809PubMedGoogle Scholar

  • 49.

    Donnelly JP, Novakova IRO, Raemakers JMM, De Pauw BE (1993) Empiric treatment of localized infections in the febrile neutropenic patients with monotherapy. Leuk Lymphoma 9:193–203PubMedGoogle Scholar

  • 50.

    Castagnola E, Fontanma V, Caviglia I et al (2007) A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hematopoietic stem cell transplantation. Clin Infect Dis 45:1296–1304PubMedGoogle Scholar

  • 51.

    Viscoli C, Bruzzi P, Castagnola E et al (1994) Factors associated with bacteremia in febrile granulocytopenic cancer patients. Eur J Cancer 30:430–437Google Scholar

  • 52.

    De Pauw BE, Donnelly JP, Elves A et al (1990) Towards individually tailored empiric antibiotic therapy in febrile granulocytopenic patients. Neth J Med 37:111–119PubMedGoogle Scholar

  • 53.

    Cordonnier C, Buzyn A, Leverger G et al (2003) Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 36:149–158PubMedGoogle Scholar

  • 54.

    Kern W, Jurrie E, Schmeiser T (1990) Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection 18:138–145PubMedGoogle Scholar

  • 55.

    Engelhard D, Elishoov H, Or R et al (1995) Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant 16:565–570PubMedGoogle Scholar

  • 56.

    Bochut P-Y, Calandra T, Francioli P (1994) Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 97:256–264Google Scholar

  • 57.

    Blijlevens NMA, Donnelly JP, De Pauw BE (2000) Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 25:2469–2478Google Scholar

  • 58.

    Pouwels MJM, Donnelly JP, Raemaekers JMM, Verweij PE, De Pauw BE (1997) Clostridium septicum sepsis and neutropenic enterocolitis in a patient treated with intensive chemotherapy for acute myeloid leukemia. Ann Hematol 74:153–157Google Scholar

  • 59.

    Tikko SK, Distenfield A, Davidson M (1985) Clostridium septicum septicemia with identical metastatic myonecroses in a granulocytopenic patient. Am J Med 79:256–258PubMedGoogle Scholar

  • 60.

    Gerard M, Defresne N, Daneau D et al (1988) Incidence and significance of Clostridium difficile in hospitalized cancer patients. Eur J Clin Microbiol Infect Dis 7:274–278PubMedGoogle Scholar

  • 61.

    Rampling A, Warren RE, Bevan PC et al (1985) Clostridium difficile in haematological malignancy. J Clin Pathol 38:445–451PubMedGoogle Scholar

  • 62.

    Delmé M, Vandercam B, Avesani V et al (1987) Epidemiology and prevention of Clostridium difficile infection in a leukemia unit. Eur J Clin Microbiol 6:623–627Google Scholar

  • 63.

    Heard SR, O’Farrell S, Holland D et al (1986) The epidemiology of Clostridium difficile with use of a typing scheme: nosocomial acquisition and cross-infection among immunocompromised patients. J Infect Dis 153:159–162PubMedGoogle Scholar

  • 64.

    Gorschlüter M, Glasmacher A, Hahn C et al (2001) Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 33:786–791PubMedGoogle Scholar

  • 65.

    Luft BJ, Remington JS (1985) Toxoplasmosis of the central nervous system. Curr Clin Top Infect Dis 6:315–358Google Scholar

  • 66.

    Longworth DL, Weller PF (1986) Hyperinfection syndrome with strongyloidiasis. Curr Clin Top Infect Dis 7:1–26Google Scholar

  • 67.

    Sanders CC (1991) New b-lactams: new problems for the internist. Ann Intern Med 115:650–651PubMedGoogle Scholar

  • 68.

    Muder RR, Harris AP, Muller S et al (1996) Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective multicenter study of 91 episodes. Clin Infect Dis 22:508–512PubMedGoogle Scholar

  • 69.

    Anaissie E (1992) Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 43(Suppl 1):14–53Google Scholar

  • 70.

    Fine JD, Miller JA, Harrist TJ et al (1981) Cutaneous lesions in disseminated candidiasis mimicking ecthyma gangrenosum. Am J Med 70:1133–1135PubMedGoogle Scholar

  • 71.

    Bodey GP, Jadeja L, Elting L (1985) Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Int Med 145:1621–1629Google Scholar

  • 72.

    Suster S, Rose LB (1987) Intradermal bullous dermatitis due candidiasis in an immunocompromised patient. JAMA 258:2106–2107PubMedGoogle Scholar

  • 73.

    Hay CRM, Messenger AG, Cotton DWK et al (1987) Atypical bullous pyoderma gangrenosum associated with myeloid malignancies. J Clin Pathol 40:387–392PubMedGoogle Scholar

  • 74.

    Cohen PR, Kurzrock R (1987) Sweet’s syndrome and malignancy. Am J Med 82:1120–1126Google Scholar

  • 75.

    Bookman MA, Longo DL (1986) Concomitant illness in patients treated for Hodgkin’s disease. Cancer Treat Rev 13:77–111PubMedGoogle Scholar

  • 76.

    Miliauskas JR, Webber BL (1984) Disseminated varicella at autopsy in children with cancer. Cancer 53:1518–1525PubMedGoogle Scholar

  • 77.

    Strauss SE (1988) Varicella zoster virus infections: biology, natural history, treatment and prevention. Ann Intern Med 108:221–237Google Scholar

  • 78.

    Lordick F, Hentrich M, Decker T et al (2003) Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. Br J Haematol 120(6):1073–1078PubMedGoogle Scholar

  • 79.

    Overholser CD, Peterson DE, William LT et al (1982) Periodontal infections in patients with acute nonlymphocytic leukemia: prevalence of acute exacerbations. Arch Intern Med 142:551–554PubMedGoogle Scholar

  • 80.

    Bergmann OJ (1989) Oral infections and fever in immunocompromised patients with haematologic malignancies. Eur J Clin Microbiol Infect Dis 8:207–213PubMedGoogle Scholar

  • 81.

    Noriega LM, van der Auwera P, Phan M et al (1993) Anaerobic bacteremia in a cancer center. Support Care Cancer 1:250–255PubMedGoogle Scholar

  • 82.

    Corey L, Spear PG (1986) Infections with herpes simplex viruses. N Engl J Med 314:686–691, 749–757Google Scholar

  • 83.

    Shelhamer JH, Toews GB, Masur H et al (1992) Respiratory disease in the immunosuppressed patient. Am Intern Med 117:415–431Google Scholar

  • 84.

    Nováková IRO, Donnelly JP, De Pauw B (1993) Potential sites of infection that develop in febrile neutropenic patients. Leuk Lymphoma 10:461–467PubMedGoogle Scholar

  • 85.

    Varthalitis I, Meunier F (1993) Pneumocystis carinii pneumonia in cancer patients. Cancer Treat Rev 19:387–413PubMedGoogle Scholar

  • 86.

    Hughes WT, Rivera GK, Schell MJ et al (1987) Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316:1627–1632PubMedGoogle Scholar

  • 87.

    Whimbey E, Couch RB, Englund JA et al (1995) Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 21:376–379PubMedGoogle Scholar

  • 88.

    Whimbey E, Champlin RE, Couch RB et al (1996) Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 22:778–782PubMedGoogle Scholar

  • 89.

    Schimpff SC, Greene WH, Young VM et al (1973) Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur J Cancer 9:449–455PubMedGoogle Scholar

  • 90.

    Vidal F, Mensa J, Almela M et al (1996) Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis in the influence of antibiotic treatment. Analysis of 189 episodes. Arch Int Med 156:2121–2126Google Scholar

  • 91.

    Ampel NM, Wing EJ (1988) Legionellosis in the compromised host. In: Rubin RH, Young LS (eds) Clinical approach to infection in the compromised host, 2nd edn. Plenum, New York, pp 305–319Google Scholar

  • 92.

    Mayaud C, Cadranel J (2000) A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised host. Thorax 55:511–517PubMedGoogle Scholar

  • 93.

    Johnson MP, Ramphal R (1990) Malignant external otitis: report on therapy with ceftazidime and review of therapy and prognosis. Rev Infect Dis 12:173–180PubMedGoogle Scholar

  • 94.

    Chang J, Powles R, Mehta J, Paton S, Treleaven J, Jameson B (1995) Listeriosis in the bone marrow transplant recipient. Clin Infect Dis 21:1289–1290PubMedGoogle Scholar

  • 95.

    Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMedGoogle Scholar

  • 96.

    Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational Association for supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMedGoogle Scholar

  • 97.

    Vidal L, Paul M, Ben dor I, Pokroy E, Soares-Weiser K, Leibovici L (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 54:29–37PubMedGoogle Scholar

  • 98.

    Malik IA, Abbas Z, Karim M (1992) Randomised comparison of oral ofloxacin alone with a combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339:1092–1096PubMedGoogle Scholar

  • 99.

    Rubenstein EB, Rolston K, Benjamin RS (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640–3646PubMedGoogle Scholar

  • 100.

    Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114PubMedGoogle Scholar

  • 101.

    Malik IA, Khan WA, Karim M, Azziz Z, Khan MA (1995) Feasibility of outpatient management of fever in cancer patient with low-risk neutropenia: results of a prospective randomized trial. Am J Med 98:224–231PubMedGoogle Scholar

  • 102.

    Horowitz DW, Holmgren D, Seiter K (1996) Stepdown single antibiotic therapy for the management of the high risk adult with hematologic malignancies. Leuk Lymphoma 23:159–163PubMedGoogle Scholar

  • 103.

    Aquino VM, Tkaczewski I, Buchanan GR (1997) Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 25:74–78PubMedGoogle Scholar

  • 104.

    Jones GR, Konsler GK, Dunaway RP, Gold SH, Cooper HA, Wells RJ (1994) Risk factors for recurrent fever after discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr 124:703–708PubMedGoogle Scholar

  • 105.

    Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G (1996) The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 77:791–798PubMedGoogle Scholar

  • 106.

    Su F, Nguyen ND, Wang Z, Cay Y, Rogiers P, Vincent J-L (2005) Fever control in septic shock: beneficial or harmful? Shock 23:516–520PubMedGoogle Scholar

  • 107.

    Kreger BE, Craven DE, McCabe WR (1980) Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68:344–355PubMedGoogle Scholar

  • 108.

    O’ Hanley P, Easaw J, Rugo H, Easaw S (1989) Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med 87:605–613Google Scholar

  • 109.

    De Pauw BE, Dompeling EC (1996) Antibiotic strategy after the empiric phase in patients treated for a hematological malignancy. Ann Hematol 72:273–279PubMedGoogle Scholar

  • 110.

    Akova M, Paesmans M, Calandra T, Viscoli C, International Antimicrobial Therapy Group of the European Organization of Research and Treatment of Cancer (2005) A European Organization for Research and treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis 40:239–245PubMedGoogle Scholar

  • 111.

    Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG (1984) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101–107Google Scholar

  • 112.

    EORTC International Antimicrobial Therapy Cooperative Group (1989) Empiric antifungal therapy in febrile neutropenic patients. Am J Med 86:668–672Google Scholar

  • 113.

    Edwards JE, Bodey GP, Bowden RA et al (1997) International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 25:43–59PubMedGoogle Scholar

  • 114.

    Kuse E-R, Chetchotisakd P, Arns da Cunha C, Micafungin Invasive Candidiasis Working Group et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519–1527PubMedGoogle Scholar

  • 115.

    Kullberg BJ, Sobel JD, Ruhnke M et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435–1442PubMedGoogle Scholar

  • 116.

    Sobel JD, Revankar SG (2007) Echinocandins – first-choice or first-line therapy for invasive candidiasis? N Engl J Med 356:2525–2526PubMedGoogle Scholar

  • 117.

    Walsh TJ, Hathorn JW, Sobel JD et al (1991) Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med 324:1026–1031PubMedGoogle Scholar

  • 118.

    Verweij PE, Stynen D, Rijs AJMM, de Pauw BE, Hoogkamp-Korstanje JA, Meis JF (1995) Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 33:1912–1914PubMedGoogle Scholar

  • 119.

    Pagano L, Caira M, Nosari A et al (2007) Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine nelle Empatie Maligne. Clin Infect Dis 45:1161–1170PubMedGoogle Scholar

  • 120.

    Verweij PE, Rijs AJMM, De Pauw BE, Horrevorts AM, Hoogkamp-Korstanje JAA, Meis JFGM (1995) Clinical evaluation and reproducibility of the Pastorex Aspergillus antigen latex agglutination test for diagnosing invasive aspergillosis. J Clin Pathol 48:474–476PubMedGoogle Scholar

  • 121.

    Maertens J, Theunissen K, Verhoef G et al (2005) Galactomannan and ­computed ­tomography-based preemptive antifungal therapy in neutropenic patients at risk of ­invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41:1242–1250PubMedGoogle Scholar

  • 122.

    De Pauw BE (2005) Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 41:1251–1253PubMedGoogle Scholar

  • 123.

    Oshima K, Kanda Y, Asono-Mori Y et al (2007) Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 60:350–355PubMedGoogle Scholar

  • 124.

    Greene RE, Schlamm HT, Oestmann J-W et al (2007) Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44:373–379PubMedGoogle Scholar

  • 125.

    Kuhlman JE, Fishman EK, Siegelman SS (1985) Invasive pulmonary aspergillosis in acute leukemia: characteristics findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology 157:611–614PubMedGoogle Scholar

  • 126.

    Caillot D, Casasnovas O, Bernard A et al (1997) Improved management of invasive pulmonary Aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15:139–147PubMedGoogle Scholar

  • 127.

    Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909–917PubMedGoogle Scholar

  • 128.

    Kontoyiannis DP, Lionakis MS, Lewis RE et al (2005) Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191:1350–1360PubMedGoogle Scholar

  • 129.

    Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359PubMedGoogle Scholar

  • 130.

    Cornely OA, Maertens J, Bresnik M, AmBiLoad Trial Study Group et al (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 44:1289–1297PubMedGoogle Scholar

  • 131.

    Meunier F, Aoun M, Bitar N (1992) Candidemia in immunocompromised patients. Clin Infect Dis 14(Suppl 1):S120–S125PubMedGoogle Scholar

  • 132.

    Girmenia C, Martino P, De Bernardis F et al (1996) Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 23:506–514PubMedGoogle Scholar

  • 133.

    Thaler M, Pastakia B, Shawker TH, O’Leary T, Pizzo PA (1988) Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 108:88–100PubMedGoogle Scholar

  • 134.

    Anaissie EJ, Vartivarian SE, Abi-Said D et al (1996) Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 101:170–176PubMedGoogle Scholar

  • 135.

    Walsh TJ, Pizzo PA (1989) Fungal infections in granulocytopenic patients: current approaches to classification, diagnosis, and treatment. In: Holmberg K, Meyer R (eds) Diagnosis and therapy of systemic fungal infections. Raven, New York, pp 47–70Google Scholar

  • 136.

    Krcmery V, Jesenska Z, Spanik S et al (1997) Fungemia due to Fusarium spp in cancer patients. J Hosp Infect 36:223–228PubMedGoogle Scholar

  • 137.

    Boutati EI, Anaissie EJ (1997) Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood 90:999–1008PubMedGoogle Scholar

  • 138.

    Maher DW, Lieschke GJ, Green M et al (1994) Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo controlled trial. Ann Intern Med 121:492–501PubMedGoogle Scholar

  • 139.

    Anaissie EJ, Vartivarian S, Bodey GP et al (1996) Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia. Am J Med 100:17–23PubMedGoogle Scholar

  • 140.

    American Society of Clinical Oncology (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14:1957–1960Google Scholar

  • 141.

    Croockewit AJ, Bronchud MH, Aapro MS et al (1997) A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. Eur J Cancer 33:1732–1746PubMedGoogle Scholar

  • 142.

    Levenga TH, Timmer-Bonte JNH (2007) Review of the value of colony stimulating factors for the prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies. Br J Haematol 138:146–152PubMedGoogle Scholar

  • 143.

    Ellis M, Zwaan F, Hedstrom U et al (2003) Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet 25:275–280Google Scholar

  • 144.

    Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancer. N Engl J of Med 351:2590–2598Google Scholar

  • 145.

    Beaven AW, Shea TC (2006) Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for hematological malignancies. Expert Opin Pharmacother 7:2287–2299PubMedGoogle Scholar

  • 146.

    Joshi JH, Schimpff SC, Tenney JH et al (1984) Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 76:450–457PubMedGoogle Scholar

  • 147.

    Oude Lashof AML, Donnelly JP, Meis JFGM, van der Meer JWM, Kullberg BJ (2003) Duration of antifungal treatment and development of delayed complications in patients with candidaemia. J Haematol 22:43–48Google Scholar

  • 148.

    Karp JE, Burch PA, Merz WG (1988) An approach to intensive antileukemic therapy in patients with previous invasive aspergillosis. Am J Med 85:203–206PubMedGoogle Scholar

  • 149.

    Offner F, Cordonnier C, Ljungman P et al (1998) Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 26:1098–1103PubMedGoogle Scholar

  • 150.

    Nosari A, Ravini M, Cairoli R et al (2007) Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant 39:631–635PubMedGoogle Scholar


Source: https://link.springer.com/chapter/10.1007/978-1-59745-415-5_5


BUY NOW For Sale 70%!
buy viagra

Handmade trend blog - Trend Tablet Cipro side effect itching

Fraxiparine renal dose ciprofloxacin DNA Methylation Analysis by Pyrosequencing - Springer
Fraxiparine renal dose ciprofloxacin ONYC Hair UK - Cipro El Salvador Doblaje Candidatos
Fraxiparine renal dose ciprofloxacin Cipro candelaria capitulo 4a
Fraxiparine renal dose ciprofloxacin Sms Via Cipro Milano - The Foundation For Civil Society
Fraxiparine renal dose ciprofloxacin Fragen @
Новости Previsioni Meteo Per Mesaria - Fino a 7 Giorni 3B Meteo Banche in crisi: cosa rischiano (davvero) i clienti - Panorama Can Cipro cause Gastroparesis? - Treato Ciprofloxacin - Antibiotics Home Page
BUY NOW For Sale 70%!
buy viagra